Bayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped prevent the disease from spreading, in a niche where Pfizer and Johnson ...

In ARAMIS, the median MFS was 40.4 months in the darolutamide arm compared to 18.4 months in the placebo arm, which is equivalent to a 59% reduction in the risk of metastases or death.

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer ...